Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/38517
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFANG, Marcel
dc.contributor.authorMARTA, Gustavo Nader
dc.date.accessioned2020-12-16T14:57:18Z-
dc.date.available2020-12-16T14:57:18Z-
dc.date.issued2020
dc.identifier.citationREVISTA DA ASSOCIACAO MEDICA BRASILEIRA, v.66, n.9, p.1301-1306, 2020
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/38517-
dc.description.abstractINTRODUCTION: Radiation therapy is widely used as adjuvant treatment in breast cancer patients. In the last decades, several studies have been designed to evaluate the safety and efficacy of hypofractionated breast radiation therapy. More recently, even shorter regimens with doses above 4 Gy (hyper-hypofractionation) have also been proposed. This study aims to present a narrative review of the various hypo fractionation protocols used to treat breast cancer patients with a focus on clinical application. RESULTS: Long-term results from several phase III randomized controlled trials demonstrated the safety and efficacy of hypofractionated breast radiation therapy using 15 or 16 fractions for early and locally advanced disease. The results of the initial clinical trials of hyper-hypofractionation are also encouraging and it is believed that these regimens may become routine in the indication of adjuvant radiation therapy treatment after the ongoing studies on this subject have matured. CONCLUSIONS: The idea that normal tissues could present high toxicity at doses above 2 Gy was opposed by clinical trials that demonstrated that moderate hypo fractionation had similar results regarding oncological and cosmetic outcomes compared to conventional fractionation. Cosmetic and toxicity results from hyper-fractionation studies are in principle favorable. However, the long-term oncological results of studies that used hyper-hypofractionation for the treatment of breast cancer patients are still awaited.eng
dc.language.isoeng
dc.publisherASSOC MEDICA BRASILEIRAeng
dc.relation.ispartofRevista da Associacao Medica Brasileira
dc.rightsopenAccesseng
dc.subjectRadiation therapyeng
dc.subjectBreast neoplasmseng
dc.subjectRadiation dose hypofractionationeng
dc.subject.otherradiotherapy hypofractionationeng
dc.subject.otheruk standardizationeng
dc.subject.otherelderly-womeneng
dc.subject.otherirradiationeng
dc.subject.othertrialeng
dc.subject.otherfractionationeng
dc.subject.othersocietyeng
dc.subject.othersurgeryeng
dc.subject.otheroldereng
dc.titleHypofractionated and hyper-hypofractionated radiation therapy in postoperative breast cancer treatmenteng
dc.typearticleeng
dc.rights.holderCopyright ASSOC MEDICA BRASILEIRAeng
dc.identifier.doi10.1590/1806-9282.66.9.1301
dc.identifier.pmid33027462
dc.subject.wosMedicine, General & Internaleng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalFANG, Marcel:PreventSenior, Dept Radiooncol, Sao Paulo, SP, Brazil
hcfmusp.description.beginpage1301
hcfmusp.description.endpage1306
hcfmusp.description.issue9
hcfmusp.description.volume66
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000574275600025
hcfmusp.origem.id2-s2.0-85092685103
hcfmusp.origem.idSCIELO:S0104-42302020000901301
hcfmusp.publisher.citySAO PAULOeng
hcfmusp.publisher.countryBRAZILeng
hcfmusp.relation.referenceBentzen SM, 2008, LANCET, V371, P1098, DOI 10.1016/S0140-6736(08)60348-7eng
hcfmusp.relation.referenceBentzen SM, 2008, LANCET ONCOL, V9, P331, DOI [10.1016/S1470-2045(08)60348-7, 10.1016/S1470-2045(08)70077-9]eng
hcfmusp.relation.referenceBiganzoli L, 2012, LANCET ONCOL, V13, pE148, DOI 10.1016/S1470-2045(11)70383-7eng
hcfmusp.relation.referenceBrunt AM, 2016, RADIOTHER ONCOL, V120, P114, DOI 10.1016/j.radonc.2016.02.027eng
hcfmusp.relation.referenceDragun AE, 2017, INT J RADIAT ONCOL, V98, P595, DOI 10.1016/j.ijrobp.2017.01.212eng
hcfmusp.relation.referenceEarly Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2eng
hcfmusp.relation.referenceEnger SM, 2006, J CLIN ONCOL, V24, P4377, DOI 10.1200/JCO.2006.06.3065eng
hcfmusp.relation.referenceHalperin EC, 2018, PEREZ BRADYS PRINCIPeng
hcfmusp.relation.referenceHancke K, 2010, ANN ONCOL, V21, P748, DOI 10.1093/annonc/mdp364eng
hcfmusp.relation.referenceHaviland JS, 2013, LANCET ONCOL, V14, P1086, DOI 10.1016/S1470-2045(13)70386-3eng
hcfmusp.relation.referenceKirova YM, 2009, INT J RADIAT ONCOL, V75, P76, DOI 10.1016/j.ijrobp.2008.11.005eng
hcfmusp.relation.referenceMarta GN, 2019, LANCET ONCOL, V20, pE226, DOI 10.1016/S1470-2045(19)30078-6eng
hcfmusp.relation.referenceMcGale P, 2014, LANCET, V383, P2127, DOI 10.1016/S0140-6736(14)60488-8eng
hcfmusp.relation.referenceMonten C, 2017, INT J RADIAT ONCOL, V98, P922, DOI 10.1016/j.ijrobp.2017.01.229eng
hcfmusp.relation.referenceOrtholan C, 2005, INT J RADIAT ONCOL, V61, P154, DOI 10.1016/j.ijrobp.2004.04.059eng
hcfmusp.relation.referenceReboucas LM, 2019, BREAST J, V25, P953, DOI 10.1111/tbj.13372eng
hcfmusp.relation.referenceROSTOM AY, 1987, INT J RADIAT ONCOL, V13, P551, DOI 10.1016/0360-3016(87)90070-8eng
hcfmusp.relation.referenceSmith BD, 2018, PRACT RADIAT ONCOL, V8, P145, DOI 10.1016/j.prro.2018.01.012eng
hcfmusp.relation.referenceSmith BD, 2011, INT J RADIAT ONCOL, V81, P59, DOI 10.1016/j.ijrobp.2010.04.042eng
hcfmusp.relation.referenceTruong PT, 2006, AM J SURG, V191, P749, DOI 10.1016/j.amjsurg.2005.07.028eng
hcfmusp.relation.referenceWang SL, 2019, LANCET ONCOL, V20, P352, DOI 10.1016/S1470-2045(18)30813-1eng
hcfmusp.relation.referenceWeiss A, 2013, ANN SURG ONCOL, V20, P3274, DOI 10.1245/s10434-013-3115-2eng
hcfmusp.relation.referenceWhelan T, 2002, J NATL CANCER I, V94, P1143eng
hcfmusp.relation.referenceWhelan TJ, 2010, NEW ENGL J MED, V362, P513, DOI 10.1056/NEJMoa0906260eng
hcfmusp.relation.referenceYarnold J, 2005, RADIOTHER ONCOL, V75, P9, DOI 10.1016/j.radonc.2005.01.005eng
hcfmusp.relation.referenceYarnold JR, 2011, RADIOTHER ONCOL, V100, P93, DOI 10.1016/j.radonc.2011.06.026eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1806-9282
hcfmusp.citation.scopus2-
hcfmusp.scopus.lastupdate2022-04-28-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_FANG_Hypofactionated_and_hyperhypofractionated_radiation_therapy_in_postoperative_breast_2020.PDF.pdfpublishedVersion (English)416.39 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.